Levels of Albumin and Impact on Loop Diuretic and Albumin Co-administration in Heart Failure (LILAC-HF)

Abstract

ABSTRACT: Management of heart failure (HF) requires the use of loop diuretics to relieve congestion and improve symptoms. When loop diuretics alone fail to induce adequate diuresis, albumin has been proposed to enhance loop diuretic delivery and promote redistribution of fluid for excretion by the kidneys. Despite the theoretical benefits of albumin, studies suggesting its benefit in HF are scarce and the co-administration of loop diuretics and albumin remains controversial. This retrospective, observational study evaluated HF patients 18 years or older who received concomitant intravenous loop diuretic and albumin administration. The primary objective was to evaluate the association of serum albumin level with urine output (UOP) in hospitalized HF patients who received concomitant albumin and loop diuretic therapy. Secondary endpoints included total weight loss after 72-hours, and ICU and hospital lengths of stay. 276 patients were included for analysis. There was no association between initial serum albumin level and 72-hour UOP (coefficient -623.1, 95% CI -1558.6, 312.4; p=0.191) or weight difference at 72-hours (coefficient -1.0, 95% CI -2.4, 0.3; p=0.131). Lower albumin levels were associated with longer ICU (p=0.034) and hospital (p=0.039) lengths of stay. Concomitant thiazide diuretic use and increasing loop diuretic doses were associated with increased 72-hour UOP. The results of our study suggests that providers should avoid using baseline albumin levels as guidance for albumin dosing in HF. Given the lack of comparator groups, larger randomized controlled trials should be done to provide a definitive role for albumin to enhance diuresis in HF patients on intravenous loop diuretics.